Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genta Withdraws NDA For Genasense In Melanoma

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has requested a meeting with FDA to identify the next steps for further development. The move coincides with a restructuring at Genta to focus resources on the Genasense program.
Advertisement

Related Content

Abbott Taps Genentech Oncology Expertise For Two Phase I Compounds
Abbott Taps Genentech Oncology Expertise For Two Phase I Compounds
Genta Targeting Year-End Genasense NDA In Myeloma Or Lymphocytic Leukemia
Genta Targeting Year-End Genasense NDA In Myeloma Or Lymphocytic Leukemia
Aventis Taxotere For Prostate Cancer Clears FDA With 2.5 Month Survival Benefit
Aventis Taxotere For Prostate Cancer Clears FDA With 2.5 Month Survival Benefit
Genta Stops Active Marketing Of Ganite
Genasense Melanoma Progression-Free Survival Data Do Not Show "Real Effect," Cmte. Says
Genasense Melanoma Progression-Free Survival Data Do Not Show "Real Effect," Cmte. Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS059414

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel